LDS/Medical Tests/Methohexital, Urine

Methohexital, Urine

Methohexital is classified as a barbiturate, which is one of the oldest classes of CNS depressants. There are a wide variety of barbiturates present today and they are used mainly as sedatives, hypnotics, anticonvulsants, for migraine therapy, and the reduction of cerebral edema secondary to head injury. Methohexital is used mainly as an intravenous anesthetic.

Barbiturates are classified based on their duration of action. The ultra short-acting barbiturates are extremely potent for a short period of time, such as thiopental, thiamylal, and methohexital. The short-acting barbiturates include pentobarbital and secobarbital. The intermediate-acting are amobarbital, butalbital, and butabarbital. Methohexital is one of the short-acting barbiturates. The various classifications of barbiturates have varying therapeutic effects. For instance, the ultra-short acting barbiturates are used to induce surgical anesthesia. The short- and intermediate-acting barbiturates are used as sedative-hypnotic agents. However, due to the significant impairing effects of barbiturates, they have been replaced as sedative-hypnotic agents by benzodiazepines. The various classes of barbiturates also exhibit different, but overlapping, half-lives and some half-lives are dose dependent such as amobarbital.

Barbiturates can be administered either orally or parentally. Barbiturates undergo extensive hepatic metabolism. The intravenous route of administration is used to administer the ultrashort-acting barbiturates for induction of anesthesia. Barbiturates can elicit the following side effects: amnesia, hostility, irritability, Stevens-Johnson syndrome and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, incoordination, slow speech, impaired thinking, bradycardia, tachycardia, coma, and possible death.

Numerous methods are available to screen for barbiturate use.  Generally, immunoassays are used with antibodies that are directed toward secobarbital, and thus rely on degrees of cross-reactivity to the remaining drugs or active metabolites.  Confirmation testing can be performed by a variety of analytical methods such Gas Chromatography/Mass Spectroscopy (GC/MS) and Liquid Chromatography/Mass Spectroscopy (LC/MS).

  • Therapeutic monitoring in blood samples
  • Drug abuse evaluation
  • Toxicity assessment in blood samples
  • Patient Compliance
A qualitative positive result from an immunoassay (IA) type screening test indicates only the presence of any barbiturate such as Methohexital and is not specific and does not necessarily correlate with the extent of physiological and psychological effects. Any positive screening result must be confirmed by a confirmatory non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic levels 
Methohexital short acting class: 0.5-2.0 mg/L

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as IA, or a quantitative method such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Immunoassay (IA). The main method of quantification is via LC/MS. This particular method of analysis is used to not only detect the parent drug class of barbiturates, but is capable of detecting the major metabolites. Methohexital, similar to all barbiturates, can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. Methohexital is not extensively bound to protein and usually appears in the urine as the glucuronide conjugate. When analyzing urine specimens a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 1-3 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Pain drug management pharmacogenomics panel or CYP3A4, CYP3A5, CYP2D6 should be tested for drug safety and efficacy before ordered. Supportive testing such as Liver profile, Kidney profile, Comprehensive Metabolic Panel, CBC (if overdose), other drugs if necessary.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
  • Ann Clin Biochem. 1997 Sep;34 ( Pt 5):460-510. [PMID: 9293303]
  • Cochrane Database Syst Rev. 2012 Jul 11;7:CD007139. [PMID: 22786504]
  • Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
  • Urine Testing for Drug Abuse. National Institute on Drug Abuse (NIDA) Research Monograph. 73, 1986.
  • Baselt RC, Ed. Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Lettleton, MA: PSG Publising Co. (1987).
  • Principles of Forensic Toxicology, Fourth Edition. Ed, Barry Levine, AACC Press, Washington DC, Chapter 14, Benzodiazepines, pp. 237-251 (2013).
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, Eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill Co. (1996).
  • Baselt RC, Ed. Disposition of Toxic Drugs and Chemicals in Man, 6th ed. Foster City, CA: Biomedical Publications (2002).
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology 1989;11(4): 7-20.